PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA; Department of Health Systems Science, Kaiser Permanente Bernard J Tyson School of Medicine, Pasadena, CA, USA. Electronic address: sara.y.tartof@kp.org.\', \'Department of Research and Evaluation, Kaiser Permanente Southern California, Pasadena, CA, USA.\', \'Department of Pediatric Infectious Diseases, Southern California Permanente Medical Group, Harbor City, CA, USA.\', \'Kaiser Permanente Center for Integrated Health Care Research, Honolulu, HI, USA.\', \'Pfizer, Collegeville, PA, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • S0140-6736(21)02183-810.1016/S0140-6736(21)02183-8
?:doi
?:hasPublicationType
?:journal
  • Lancet (London, England)
is ?:pmid of
?:pmid
?:pmid
  • 34619098
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all